Building on a string of successful exits with its sixth and largest fund, Pontifax Venture Capital will now have a larger reserve of capital to maintain its ownership stakes in portfolio companies into the growth...

KSQ is setting a path to advance targeted oncology and immuno-oncology programs emerging from its CRISPR-based target discovery platform with the appointment of Qasim Rizvi as its new CEO and a recent deal with Takeda. Under...

Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in January 2018 to integrate new...

After more than three years in stealth mode during which it subsisted on a $50 million series A round from Deerfield, Nuvalent is headed into the clinic with two targeted programs for non-small cell lung...

With its oncology business in the rear view mirror, Agios is readying its first non-cancer candidate for a regulatory submission with more data in a rare anemia. After the bell Tuesday, Agios Pharmaceuticals Inc. (NASDAQ:AGIO)...

Under a new deal with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), Sanofi (Euronext:SAN; NASDAQ:SNY) will produce more than 100 million doses of COVID-19 vaccine Cormirnaty in Europe in 2021. Sanofi spokesperson Nicolas Kressmann said...

The U.S. remains the hotbed of COVID-19 therapeutics testing, but China is conducting almost as many vaccine trials.  As of Jan. 25, there were over 700 active COVID trials listed in public registries that had...

Controversy over a reduction in projected shipments of AstraZeneca’s COVID-19 vaccine to the EU have prompted the European bloc to propose a scheme that would require vaccine manufacturers to notify the EU government head of...

Macrophages are emerging as one of the hottest tools in the fight against cancer, but Resolution is targeting a new application for the cells: attacking fibrosis.  The Syncona-backed company launched...

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the successes and limitations of Operation Warp Speed, proposals for streamlining master protocol trials and highlights for industry from the Biden administration’s COVID-19...